CA2172605A1 - Dispositif transdermique renfermant la (e)-2-(p-fluorophenethyl)-3-fluoroallylamine pour le traitement de la maladie d'alzheimer - Google Patents

Dispositif transdermique renfermant la (e)-2-(p-fluorophenethyl)-3-fluoroallylamine pour le traitement de la maladie d'alzheimer

Info

Publication number
CA2172605A1
CA2172605A1 CA002172605A CA2172605A CA2172605A1 CA 2172605 A1 CA2172605 A1 CA 2172605A1 CA 002172605 A CA002172605 A CA 002172605A CA 2172605 A CA2172605 A CA 2172605A CA 2172605 A1 CA2172605 A1 CA 2172605A1
Authority
CA
Canada
Prior art keywords
fluoroallylamine
fluorophenethyl
transdermal device
disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002172605A
Other languages
English (en)
Inventor
Ian A. Mcdonald
Michael G. Palfreyman
Daniel H-S. Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2172605A1 publication Critical patent/CA2172605A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé de traitement de la maladie d'Alzheimer chez un individu consistant à administrer par voie transdermique audit individu une dose thérapeutiquement efficace de (E)-2-(p-fluorophénéthyle)-3-fluoroallylamine ou d'un de ses sels acceptable pharmaceutiquement. Elle concerne également un dispositif transdermique servant à administrer la (E)-2-(p-fluorophénéthyle)-3-fluoroallylamine ou un de ses sels acceptable pharmaceutiquement.
CA002172605A 1993-09-24 1994-08-23 Dispositif transdermique renfermant la (e)-2-(p-fluorophenethyl)-3-fluoroallylamine pour le traitement de la maladie d'alzheimer Abandoned CA2172605A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12719093A 1993-09-24 1993-09-24
US08/127,190 1993-09-24

Publications (1)

Publication Number Publication Date
CA2172605A1 true CA2172605A1 (fr) 1995-03-30

Family

ID=22428772

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002172605A Abandoned CA2172605A1 (fr) 1993-09-24 1994-08-23 Dispositif transdermique renfermant la (e)-2-(p-fluorophenethyl)-3-fluoroallylamine pour le traitement de la maladie d'alzheimer

Country Status (10)

Country Link
EP (1) EP0720475A1 (fr)
JP (1) JPH09505276A (fr)
CN (1) CN1131390A (fr)
AU (1) AU684545B2 (fr)
CA (1) CA2172605A1 (fr)
HU (1) HUT75877A (fr)
IL (1) IL111017A0 (fr)
NO (1) NO961180L (fr)
WO (1) WO1995008325A1 (fr)
ZA (1) ZA947262B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100479405B1 (ko) * 2002-05-24 2005-03-30 주식회사 싸이제닉 신남산 이합체, 그 제조방법 및 퇴행성 뇌질환 치료를위한 그의 용도
WO2010033045A1 (fr) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions et procédés pour la prévention ou le traitement d’un dépôt bêta-amyloïde

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
WO1993024120A1 (fr) * 1992-05-27 1993-12-09 Merrell Dow Pharmaceuticals Inc. UTILISATION DE (E)-2-(p-FLUOROPHENETHYLE)-3-FLUOROALLYLAMINE DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

Also Published As

Publication number Publication date
WO1995008325A1 (fr) 1995-03-30
ZA947262B (en) 1995-05-23
JPH09505276A (ja) 1997-05-27
AU7636494A (en) 1995-04-10
IL111017A0 (en) 1994-11-28
HUT75877A (en) 1997-05-28
EP0720475A1 (fr) 1996-07-10
NO961180D0 (no) 1996-03-22
HU9600725D0 (en) 1996-05-28
NO961180L (no) 1996-03-22
CN1131390A (zh) 1996-09-18
AU684545B2 (en) 1997-12-18

Similar Documents

Publication Publication Date Title
US6312716B1 (en) Patch and method for transdermal delivery of bupropion base
EP2494966B2 (fr) Composition stable de rasagiline
US8501727B2 (en) Short acting benzothiazepine calcium channel blockers and uses thereof
JP2010215643A (ja) ３，３−ジフェニルプロピルアミンモノエステルの高純度の塩基
ZA200506056B (en) Formulation and methods for the treatment of thrombocythemia
CA1257837A (fr) Produit pharmaceutique topique
TWI742628B (zh) 一種阿哌沙班透皮釋放系統及其使用方法
US20230255923A1 (en) Short acting phenylalkylamine calcium channel blockers and uses thereof
EP2650019B1 (fr) Timbre transdermique contenant un antidépresseur noradrénergique et sérotoninergique spécifique
EP0642338B1 (fr) UTILISATION DE (E)-2-(p-FLUOROPHENETHYLE)-3-FLUOROALLYLAMINE DANS LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
AU684545B2 (en) Transdermal device containing (E)-2-(P-fluorophenethyl)-3-fluoroallylamine for the treatment of Alzheimer's disease
US6608080B1 (en) Morphan derivatives or salts thereof and medicinal compositions containing the same
HU212502B (en) Process for producing pharmaceutical preparative containing n-methyl-2-(3-pyridyl)-tetrahydrothiopyrane-2-carbothioamide-1-oxide applicable for treating insufficiency of coronary arteries
EP0315217A2 (fr) Composition pharmaceutique
CA2056621A1 (fr) Administration intranasale d'indolines 3,3 disubstituees

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20000802